Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- PMID: 29573941
- DOI: 10.1016/S1470-2045(18)30142-6
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Abstract
Background: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.
Methods: COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older and had histologically confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a BRAFV600E or BRAFV600K mutation; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and were treatment naive or had progressed on or after previous first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) via interactive response technology to receive either oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). The primary endpoint was progression-free survival by blinded independent central review for encorafenib plus binimetinib versus vemurafenib. Efficacy analyses were by intention-to-treat. Safety was analysed in patients who received at least one dose of study drug and one postbaseline safety assessment. The results of part 2 will be published separately. This study is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38.
Findings: Between Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to either the encorafenib plus binimetinib group (n=192), the encorafenib group (n=194), or the vemurafenib group (n=191). With a median follow-up of 16·6 months (95% CI 14·8-16·9), median progression-free survival was 14·9 months (95% CI 11·0-18·5) in the encorafenib plus binimetinib group and 7·3 months (5·6-8·2) in the vemurafenib group (hazard ratio [HR] 0·54, 95% CI 0·41-0·71; two-sided p<0·0001). The most common grade 3-4 adverse events seen in more than 5% of patients in the encorafenib plus binimetinib group were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased creatine phosphokinase (13 [7%]), and hypertension (11 [6%]); in the encorafenib group they were palmoplantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and in the vemurafenib group it was arthralgia (11 [6%] of 186 patients). There were no treatment-related deaths except for one death in the combination group, which was considered possibly related to treatment by the investigator.
Interpretation: Encorafenib plus binimetinib and encorafenib monotherapy showed favourable efficacy compared with vemurafenib. Overall, encorafenib plus binimetinib appears to have an improved tolerability profile compared with encorafenib or vemurafenib. Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma.
Funding: Array BioPharma, Novartis.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Comment in
-
Is there any interest in a new BRAF-MEK inhibitor combination in melanoma?Lancet Oncol. 2018 May;19(5):580-581. doi: 10.1016/S1470-2045(18)30161-X. Epub 2018 Mar 21. Lancet Oncol. 2018. PMID: 29573940 No abstract available.
-
Encorafenib - a new agent for advanced-stage disease.Nat Rev Clin Oncol. 2018 Jun;15(6):344-345. doi: 10.1038/s41571-018-0019-x. Nat Rev Clin Oncol. 2018. PMID: 29651128 No abstract available.
Similar articles
-
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Lancet Oncol. 2018. PMID: 30219628 Clinical Trial.
-
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.Eur J Cancer. 2024 Jun;204:114073. doi: 10.1016/j.ejca.2024.114073. Epub 2024 Apr 24. Eur J Cancer. 2024. PMID: 38723373 Clinical Trial.
-
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.Eur J Cancer. 2019 Sep;119:97-106. doi: 10.1016/j.ejca.2019.07.016. Epub 2019 Aug 19. Eur J Cancer. 2019. PMID: 31437754 Clinical Trial.
-
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.Expert Rev Clin Pharmacol. 2019 Mar;12(3):259-266. doi: 10.1080/17512433.2019.1570847. Epub 2019 Jan 24. Expert Rev Clin Pharmacol. 2019. PMID: 30652516 Review.
-
Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.Expert Opin Drug Saf. 2020 Oct;19(10):1229-1236. doi: 10.1080/14740338.2020.1817376. Epub 2020 Sep 14. Expert Opin Drug Saf. 2020. PMID: 32857940 Review.
Cited by
-
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP.J Pathol Transl Med. 2024 Jul;58(4):147-164. doi: 10.4132/jptm.2023.11.01. Epub 2024 Jan 10. J Pathol Transl Med. 2024. PMID: 39026440 Free PMC article. Review.
-
Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma.Curr Oncol Rep. 2024 Jun 5. doi: 10.1007/s11912-024-01547-0. Online ahead of print. Curr Oncol Rep. 2024. PMID: 38837107 Review.
-
[Side effects of dermato-oncologic therapies].Dermatologie (Heidelb). 2024 Jun;75(6):466-475. doi: 10.1007/s00105-024-05354-3. Epub 2024 May 27. Dermatologie (Heidelb). 2024. PMID: 38802653 Review. German.
-
Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors.Elife. 2024 May 14;13:RP95481. doi: 10.7554/eLife.95481. Elife. 2024. PMID: 38742856 Free PMC article.
-
RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Int J Mol Sci. 2024 Apr 24;25(9):4633. doi: 10.3390/ijms25094633. Int J Mol Sci. 2024. PMID: 38731852 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous